Theriva Biologics, Inc. (TOVX)
USD 1.17
(-1.68%)
USD 1.17
(-1.68%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.99 Million | -19.08 Million | -12.89 Million | -12.16 Million | -13.87 Million | -17.27 Million |
| Net Income | -18.34 Million | -19.68 Million | -14.26 Million | -10.11 Million | -15.38 Million | -13.42 Million |
| Depreciation & Amortization | 135 Thousand | 85 Thousand | 87 Thousand | 201 Thousand | 240 Thousand | 272 Thousand |
| Deferred income taxes | -1.64 Million | -1.42 Million | -952 Thousand | - | - | -4.08 Million |
| Stock-based compensation | 552 Thousand | 475 Thousand | 416 Thousand | 350 Thousand | 340 Thousand | 2.07 Million |
| Change in working capital | 2.3 Million | -806 Thousand | 875 Thousand | -2.78 Million | 855 Thousand | -2.19 Million |
| Other non-cash items | -2 Million | 2.27 Million | 952 Thousand | 178 Thousand | 72 Thousand | 71 Thousand |
| Investing Cash Flow | -202 Thousand | -4.39 Million | -14 Thousand | -9000.00 | - | -7000.00 |
| Investments in PPE | -202 Thousand | -116 Thousand | -14 Thousand | -9000.00 | - | -7000.00 |
| Acquisitions | - | -4.28 Million | - | - | - | - |
| Investment purchases | - | -417 Thousand | - | - | - | - |
| Sales/Maturities of investments | - | 421.28 Thousand | - | - | - | - |
| Other Investing Activities | - | -4280.00 | - | - | - | - |
| Financing Cash Flow | 625 Thousand | -1.93 Million | 74 Million | 3.35 Million | - | 29.08 Million |
| Debt repayment | -75 Thousand | -1.37 Million | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -288 Thousand | - | - | - | - |
| Common Stock Issuance | 2.21 Million | 2 Million | 65.96 Million | 3.35 Million | - | 29.08 Million |
| Other Financing Activities | -1.51 Million | -2.27 Million | 8.04 Million | 3359.00 | - | 16.91 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -157 Thousand | -385 Thousand | -363 Thousand | -1.42 Million | 1.28 Million | -987 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 2.46 Million | -421 Thousand | 1.23 Million | -1.35 Million | -427 Thousand | -1.2 Million |
| Cash at beginning of period | 41.78 Million | 67.32 Million | 6.22 Million | 15.04 Million | 28.91 Million | 17.11 Million |
| Cash at end of period | 23.17 Million | 41.88 Million | 67.32 Million | 6.22 Million | 15.04 Million | 28.91 Million |
| Capital Expenditure | -202 Thousand | -116 Thousand | -14 Thousand | -9000.00 | - | -7000.00 |
| Effect of forex changes on cash | -33 Thousand | -32 Thousand | - | - | - | - |
| Net cash flow / Change in cash | -18.6 Million | -25.44 Million | 61.09 Million | -8.81 Million | -13.87 Million | 11.8 Million |
| Free Cash Flow | -19.19 Million | -19.19 Million | -12.9 Million | -12.17 Million | -13.87 Million | -17.28 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -8.31 Million | -5.16 Million | -5.48 Million | -18.34 Million | -3.3 Million | -5.08 Million |
| Depreciation & Amortization | 38 Thousand | 39 Thousand | 39 Thousand | 135 Thousand | 32 Thousand | 32 Thousand |
| Deferred income taxes | -221 Thousand | -223 Thousand | -424 Thousand | -1.64 Million | -527 Thousand | -359 Thousand |
| Stock-based compensation | 172 Thousand | 160 Thousand | 145 Thousand | 552 Thousand | 135 Thousand | 146 Thousand |
| Change in working capital | 991 Thousand | -2000.00 | 471 Thousand | 2.3 Million | 2.17 Million | 842 Thousand |
| Other non-cash items | 3.54 Million | 515 Thousand | -1.28 Million | -2 Million | -1.46 Million | 532 Thousand |
| Investing Cash Flow | -1000.00 | - | -56 Thousand | -202 Thousand | -129 Thousand | -9000.00 |
| Investments in PPE | -1000.00 | - | -56 Thousand | -202 Thousand | -129 Thousand | -9000.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 1.77 Million | - | -1.45 Million | 625 Thousand | 1000.00 | 2.13 Million |
| Debt repayment | -67 Thousand | - | - | -75 Thousand | - | -20 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1.84 Million | - | 62 Thousand | 2.21 Million | 1000.00 | 2.15 Million |
| Other Financing Activities | 1.77 Million | - | -1.51 Million | -1.51 Million | 1.00 | 2136.00 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 369 Thousand | -190 Thousand | -83 Thousand | -157 Thousand | 107 Thousand | 259 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 622 Thousand | 188 Thousand | 554 Thousand | 2.46 Million | 2.06 Million | 583 Thousand |
| Cash at beginning of period | 18.26 Million | 23.17 Million | 31.16 Million | 41.78 Million | 34.34 Million | 36.17 Million |
| Cash at end of period | 16.59 Million | 18.26 Million | 23.17 Million | 23.17 Million | 31.25 Million | 34.34 Million |
| Capital Expenditure | -1000.00 | - | -56 Thousand | -202 Thousand | -129 Thousand | -9000.00 |
| Effect of forex changes on cash | 12 Thousand | -38 Thousand | 76 Thousand | -33 Thousand | -11 Thousand | -63 Thousand |
| Net cash flow / Change in cash | -1.66 Million | -4.91 Million | -7.98 Million | -18.6 Million | -3.09 Million | -1.82 Million |
| Free Cash Flow | -3.45 Million | -4.88 Million | -6.59 Million | -19.19 Million | -3.08 Million | -3.9 Million |
ORXOF
1233
SGSN
RWEOY
ELEEF
INRLF